Getinge (OTCMKTS:GNGBY) Sets New 1-Year High – Here’s What Happened

Getinge (OTCMKTS:GNGBY – Get Free Report)’s stock price reached a new 52-week high during trading on Monday. The stock traded as high as $28.03 and last traded at $28.03, with a volume of 408 shares traded. The stock had previously closed at $26.82.

Wall Street Analysts Forecast Growth

GNGBY has been the topic of several recent research reports. Zacks Research cut shares of Getinge from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 17th. Pareto Securities lowered Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 24th. UBS Group began coverage on Getinge in a research note on Wednesday, September 2nd. They issued a “hold” rating for the company. Finally, Nordea Equity Research lowered Getinge from a “buy” rating to a “hold” rating in a report on Monday, August 31st. Four analysts have rated the stock with a Hold rating. According to MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Read Our Latest Report on GNGBY

Getinge Trading Up 2.3%

The company has a current ratio of 1.31, a quick ratio of 0.74 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.62 billion, a PE ratio of 25.42 and a beta of 0.89. The firm has a fifty day simple moving average of $25.38 and a two-hundred day simple moving average of $22.61.

Getinge (OTCMKTS:GNGBY – Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The company reported $0.32 earnings per share for the quarter. The firm had revenue of $875.58 million for the quarter. Getinge had a net margin of 8.20% and a return on equity of 11.55%. As a group, equities analysts expect that Getinge will post 1.36 earnings per share for the current fiscal year.

Getinge Company Profile

(Get Free Report)

Getinge AB is a Sweden-based medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support patient care, surgical procedures, infection prevention and the development and production of pharmaceuticals and other medical products.

The company’s portfolio includes equipment for intensive care and cardiovascular procedures, operating-room systems, surgical instruments, sterilization and disinfection solutions, and products used in laboratories and biopharmaceutical manufacturing.

See Also

• Five stocks we like better than Getinge
• Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
• Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
• 3 Waste Services Stocks With More Growth Than You Might Expect
• Alphabet’s $400 Billion Sell-Off Could Be the Best AI Buying Window Left in 2026

Receive News & Ratings for Getinge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Getinge and related companies with MarketBeat.com's FREE daily email newsletter.